Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis

  • Authors:
    • Jie Shen
    • Qing Wang
    • Juan Wang
    • Guo‑Hong Su
    • Sheng‑Hu Guo
    • Ya Liu
    • Zheng Wu
    • Rong‑Feng Liu
    • Xing Li
    • Xiao‑Jin Guo
    • Jing Cao
    • Yue‑Hua Zhang
    • Zhi‑Yu Wang
  • View Affiliations

  • Published online on: August 14, 2015     https://doi.org/10.3892/ol.2015.3613
  • Pages: 2403-2409
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multiple myeloma is a type of malignancy, which affects the plasma cells of the bone marrow. Recent studies have found that malignant plasma cells may express urokinase plasminogen activator (uPA) and uPA receptor (uPAR), and that initiation of proteolytic events by this system contributes to the process of invasion and destruction of the bone marrow. Studies have also suggested that the level of the soluble form of uPAR (suPAR) may act as a marker for prognosis in patients with multiple myeloma, and that there is an association between uPAR/suPAR expression, and clinical characteristics, efficacy of treatment in disease control and patient survival. In order to investigate this, the present study used flow cytometry to detect the monoclonal antibodies associated with multiple myeloma, specifically, uPAR (CD87), CD56 and CD38. Patients with multiple myeloma were divided into the following groups: The effective groups (remission and stable disease) and the ineffective group (progressive disease). suPAR expression in the effective groups was 257.6±32.47 pg/ml and 331.0±99.80 pg/ml respectively, which was not significantly different from that of the normal control group (P>0.05). By contrast, the suPAR level in the invalid group was 562.2±291.0 pg/ml, which was significantly different from the levels in the normal control group (P<0.01) and the effective groups (P<0.05). suPAR levels were positively correlated with disease stage (P<0.01), renal function (P<0.05), C‑reactive protein (P<0.005), β2‑microglobulin (P<0.001), extramedullary involvement (P<0.001), chromosome 13 deletion (P<0.01) and survival >2 years (P<0.01). They were was negatively correlated with hemoglobin concentration. No correlation was observed between uPAR expression and suPAR levels. The present study also indicated that the stage of disease and suPAR expression were independent factors, which predicted survival of <2 years. In conclusion, high suPAR expression appears to predict disease progression, a shortened survival period and early extramedullary infiltration.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 10 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shen J, Wang Q, Wang J, Su GH, Guo SH, Liu Y, Wu Z, Liu RF, Li X, Guo XJ, Guo XJ, et al: Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis. Oncol Lett 10: 2403-2409, 2015
APA
Shen, J., Wang, Q., Wang, J., Su, G., Guo, S., Liu, Y. ... Wang, Z. (2015). Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis. Oncology Letters, 10, 2403-2409. https://doi.org/10.3892/ol.2015.3613
MLA
Shen, J., Wang, Q., Wang, J., Su, G., Guo, S., Liu, Y., Wu, Z., Liu, R., Li, X., Guo, X., Cao, J., Zhang, Y., Wang, Z."Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis". Oncology Letters 10.4 (2015): 2403-2409.
Chicago
Shen, J., Wang, Q., Wang, J., Su, G., Guo, S., Liu, Y., Wu, Z., Liu, R., Li, X., Guo, X., Cao, J., Zhang, Y., Wang, Z."Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis". Oncology Letters 10, no. 4 (2015): 2403-2409. https://doi.org/10.3892/ol.2015.3613